公开(公告)号：US20220064120A1

公开(公告)日：2022-03-03

申请号：US17368766

申请日：2021-07-06

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert BICHLER ,  Jean-Jacques Alexandre CADIEUX ,  Matthew David TANDY ,  Gregory N. BEATCH

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US20210147363A1

公开(公告)日：2021-05-20

申请号：US17069386

申请日：2020-10-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert BICHLER ,  Jean-Jacques Alexandre CADIEUX ,  Matthew David TANDY ,  Gregory N. BEATCH

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US20130252962A1

公开(公告)日：2013-09-26

申请号：US13787558

申请日：2013-03-06

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Mikhail CHAFEEV ,  Sultan CHOWDHURY ,  Lauren FRASER ,  Jianmin FU ,  Jonathan LANGILLE ,  Shifeng LIU ,  Jianyu SUN ,  Shaoyi SUN ,  Serguei SVIRIDOV ,  Mark WOOD ,  Alla Yurevna ZENOVA ,  Qi JIA ,  Jean-Jacques Alexandre CADIEUX ,  Simon J. GAUTHIER ,  Amy Frances DOUGLAS ,  Tom HSIEH ,  Nagasree CHAKKA ,  Zoran CIKOJEVIC

IPC: C07D491/107 ,  C07D495/20 ,  C07D498/20 ,  C07D513/20 ,  C07D491/20

CPC classification number: C07D513/22 ,  C07D491/10 ,  C07D491/107 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D498/20 ,  C07D513/20 ,  C07D519/00

Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.